ES2396222T3 - Ésteres cristalinos hidratados de camptotecina para el tratamiento del cáncer - Google Patents

Ésteres cristalinos hidratados de camptotecina para el tratamiento del cáncer Download PDF

Info

Publication number
ES2396222T3
ES2396222T3 ES08841603T ES08841603T ES2396222T3 ES 2396222 T3 ES2396222 T3 ES 2396222T3 ES 08841603 T ES08841603 T ES 08841603T ES 08841603 T ES08841603 T ES 08841603T ES 2396222 T3 ES2396222 T3 ES 2396222T3
Authority
ES
Spain
Prior art keywords
cancer
crystalline
camptothecin
crystalline camptothecin
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08841603T
Other languages
English (en)
Spanish (es)
Inventor
Zhisong Cao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Christus Stehlin Foundation for Cancer Research
Original Assignee
Christus Stehlin Foundation for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christus Stehlin Foundation for Cancer Research filed Critical Christus Stehlin Foundation for Cancer Research
Application granted granted Critical
Publication of ES2396222T3 publication Critical patent/ES2396222T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES08841603T 2007-10-25 2008-10-24 Ésteres cristalinos hidratados de camptotecina para el tratamiento del cáncer Active ES2396222T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/923,727 US7572803B2 (en) 2007-10-25 2007-10-25 Hydrated crystalline esters of camptothecin
US923727 2007-10-25
PCT/US2008/081047 WO2009055633A1 (en) 2007-10-25 2008-10-24 Hydrated crystalline esters of camptothecin for the treatment of cancer

Publications (1)

Publication Number Publication Date
ES2396222T3 true ES2396222T3 (es) 2013-02-20

Family

ID=40229972

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08841603T Active ES2396222T3 (es) 2007-10-25 2008-10-24 Ésteres cristalinos hidratados de camptotecina para el tratamiento del cáncer

Country Status (11)

Country Link
US (1) US7572803B2 (enExample)
EP (1) EP2205605B1 (enExample)
JP (1) JP5487111B2 (enExample)
KR (1) KR20100082358A (enExample)
CN (1) CN101730701B (enExample)
BR (1) BRPI0816584A2 (enExample)
CA (1) CA2703054C (enExample)
ES (1) ES2396222T3 (enExample)
MX (1) MX2010004332A (enExample)
RU (1) RU2483071C2 (enExample)
WO (1) WO2009055633A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130121921A1 (en) 2011-11-11 2013-05-16 The Christus Stehlin Foundation For Cancer Research Rodent Therapeutic Model And Methods
US9387257B2 (en) * 2014-01-17 2016-07-12 Academia Sinica Lung cancer specific peptides for targeted drug delivery and molecular imaging
US9675609B2 (en) * 2015-11-11 2017-06-13 Cao Pharmaceuticals Inc. Nano- and micro-sized particles of 20-camptothecin or derivative thereof and pharmaceutical compositions containing same, and treatment of cancers therewith
US20220395497A1 (en) * 2019-11-20 2022-12-15 Vivacitas Oncology, Inc. Cancer Treatment Using Camptothecin Derivatives

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US6080751A (en) 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
US5352789A (en) 1993-02-25 1994-10-04 The Stehlin Foundation For Cancer Research Methods for purifying camptothecin compounds
US5527913A (en) 1993-02-25 1996-06-18 The Stehlin Foundation For Cancer Research Methods for purifying camptothecin compounds
US6407118B1 (en) 1996-01-30 2002-06-18 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
US6096336A (en) 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US5731316A (en) 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
USRE38408E1 (en) 1997-08-05 2004-01-27 The Stehlin Foundation For Cancer Research Methods of preparing and purifying 9-nitro-20-camptothecin
US5922877A (en) 1997-08-05 1999-07-13 The Stehlin Foundation For Cancer Research Methods of preparing and purifying 9-nitro-20-camptothecin
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
US6703399B2 (en) 2002-05-06 2004-03-09 The Stehlin Foundation For Cancer Research Halo-alkyl esters of camptothecins and methods of treating cancer using these compounds
US6699875B2 (en) 2002-05-06 2004-03-02 The Stehlin Foundation For Cancer Research Cascade esters of camptothecins and methods of treating cancer using these compounds
CN100418970C (zh) * 2003-02-25 2008-09-17 株式会社益力多本社 伊立替康盐酸盐的同质多晶的制造方法
AR046579A1 (es) * 2003-11-12 2005-12-14 Smithkline Beecham Corp Compuesto cristalino de topotecan, composicion farmaceutica que lo comprende, procedimiento para prepararlo y su uso para preparar dicha composicion farmaceutica
KR101150504B1 (ko) * 2005-09-20 2012-07-09 시노팜 싱가포르 피티이 리미티드 이리노테칸 염산염의 신규의 결정형

Also Published As

Publication number Publication date
BRPI0816584A2 (pt) 2015-03-03
CA2703054C (en) 2017-08-22
RU2010120810A (ru) 2011-11-27
JP2011500841A (ja) 2011-01-06
JP5487111B2 (ja) 2014-05-07
KR20100082358A (ko) 2010-07-16
EP2205605A1 (en) 2010-07-14
EP2205605B1 (en) 2012-11-21
CN101730701A (zh) 2010-06-09
RU2483071C2 (ru) 2013-05-27
MX2010004332A (es) 2010-05-20
WO2009055633A1 (en) 2009-04-30
CN101730701B (zh) 2013-05-29
US7572803B2 (en) 2009-08-11
CA2703054A1 (en) 2009-04-30
US20090111845A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
ES2332160T3 (es) Derivados de camptotecina para la utilizacion en el tratamiento del cancer.
US5916896A (en) Water-soluble esters of camptothecin compounds
US6352996B1 (en) Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US5633260A (en) 11,7 Substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
CN100406013C (zh) 喜树碱衍生物
ES2274020T3 (es) Derivados de camptotecinas nitrogenadas.
ITMI20061473A1 (it) Derivati della camptotecina ad attivita antitumorale
CA2703054C (en) Hydrated crystalline esters of camptothecin for the treatment of cancer
AU2007224896B2 (en) Camptothecin derivatives and their use
ES2246864T3 (es) Esteres de camptotecin-beta-alanina con inhibicion de la topoisemorasa i.
US20030216421A1 (en) Cascade esters of camptothecins and methods of treating cancer using these compounds
US6703399B2 (en) Halo-alkyl esters of camptothecins and methods of treating cancer using these compounds
CN108586535A (zh) 含喜树碱结构的磷脂类似物、制备方法及用途
US7071204B2 (en) Camptothecin analogs having an E-ring ketone
CN108484671A (zh) 具有喜树碱结构单元的磷脂类似物、制备方法及用途